Epstein-Barr Virus Makes Cells Immortal
Posted on: Friday, 1 April 2005, 00:00 CST
Toronto scientists have found how the Epstein-Barr virus immortalizes cells, predisposing people with the virus to develop certain types of cancer.
All cells contain the two proteins p53 and USP7. These proteins work together to regulate cell growth. P53 determines whether cells will continue to multiply or stop dividing and die as they are supposed to. USP7 binds to p53 and makes it stable.
The virus, however, has a protein called EBNA1 that binds to USP7 and interferes with the process. Cells infected with EBNA1 continue to grow and may develop into cancer.
Epstein-Barr virus is one of the most common human viruses in the world and is strongly linked to certain b-cell cancers like Burkitt's lymphoma as well as the epithelial cell cancer, nasopharyngeal carcinoma, said says Lori Frappier, the paper's senior author. This research shows how EBNA1 interferes with natural cell growth regulation by binding to a particular protein in cells, causing them to continue growing and therefore increasing the risk of becoming cancerous.
The research, lead by the University of Toronto, appears in the April 1 issue of Molecular Cell.
Source: United Press International
Related Articles
- Idera Pharmaceuticals Initiates Phase 1b Trial of IMO-2055 in Combination With Targeted Agents in Non-Small Cell Lung Cancer
- Introgen's P53 Immunotherapy Drug Candidate to Advance Into Second Phase 2 Clinical Trial in Small Cell Lung Cancer With National Cancer Institute
- Introgen Announces Positive Phase 2 Clinical Trial Results With INGN 225 Immunotherapy in Patients With Small Cell Lung Cancer
- Vion Initiates Phase II Trial of Cloretazine(R) in Small Cell Lung Cancer
- AVAX Technologies Announces the Filing of IND for the Treatment of Patients With Non Small Cell Lung Cancer
- Pivotal Phase III Tarceva Study Published in the New England Journal of Medicine Showed Survival Improvement in Advanced Non-Small Cell Lung Cancer
- STELLAR 2 and 4 Pivotal Trials Demonstrate XYOTAX(TM) Produces Equivalent Survival While Significantly Reducing Serious Side Effects in the Treatment of First- or Second-Line Non-Small Cell Lung Cancer
- The Role of Whole-Body Bone Scanning and Clinical Factors in Detecting Bone Metastases in Patients With Non-Small Cell Lung Cancer*
- The Impact of Smoking Status on the Behavior and Survival Outcome of Patients With Advanced Non-Small Cell Lung Cancer*: A Retrospective Analysis
- Point Therapeutics Achieves Interim Tumor Response Criteria in Phase 2 Non-Small Cell Lung Cancer Study; Company Advances Talabostat to Second Stage of Study
 |
 |
User Comments (0)
RSS Feeds